Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Merck
Express Scripts
Daiichi Sankyo
Fuji
Baxter

Generated: July 19, 2019

DrugPatentWatch Database Preview

Bromocriptine mesylate - Generic Drug Details

Try a free trialSee Plans and Pricing

« Back to Dashboard

What are the generic sources for bromocriptine mesylate and what is the scope of bromocriptine mesylate patent protection?

Bromocriptine mesylate is the generic ingredient in three branded drugs marketed by Lek Pharm, Mylan, Zydus Pharms Usa Inc, Us Pharms Holdings I, Paddock Llc, Sandoz Inc, and Veroscience, and is included in eight NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bromocriptine mesylate has twenty-six patent family members in thirteen countries.

There are nine drug master file entries for bromocriptine mesylate. Ten suppliers are listed for this compound.

Pharmacology for bromocriptine mesylate
Medical Subject Heading (MeSH) Categories for bromocriptine mesylate
Synonyms for bromocriptine mesylate
.alpha.-Ergocryptine, methanesulfonate
(+)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6'-18-trione methanesulfonate salt
(+)-BROMOCRIPTINE MESYLATE
(+)-Bromocriptine methanesulfonate
(+)-Bromocriptine methanesulfonate salt
(5 inverted exclamation mark |A)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione Methanesulfonate
(5'a)-2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione mesylate
(5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman methanesulfonate
(5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)ergotaman methanesulfonate (salt)
(5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman methanesulfonate
(5xi,5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman methanesulfonate (salt)
(5xi,5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman methanesulfonate (salt)
(6aR,9R)-5-Bromo-N-[(2R,5S,10aS,10bS)-10b-hydroxy-2-(1-methylethyl)-5-(2-methylpropyl)-3,6-dioxooctahydro-8H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl]-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quin
(9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate
2-Bromine-alpha-ergocryptine methanesulfonate
2-Bromo |A-Ergocryptine Mesylate
2-Bromo alpha-Ergocryptine Mesylate
2-Bromo-.alpha.-ergocryptine monomethanesulfonate
2-Bromo-|A-ergocryptine methanesulfonate salt
2-Bromo-12 -hydroxy-2 - (1-methylethyl)-5 -(2-methyl- propyl)ergotaman-3 ,6 ,18-trione methanesulfonate
2-Bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methyl-propyl)ergotaman-3',6',18-trione methanesulfonate
2-Bromo-12'-hydroxy-5'alpha-isobutyl-2'-isopropylergotaman-3',6',18-trione monomethanesulphonate
2-Bromo-a-ergocryptine methanesulfonate salt
2-Bromo-alpha-ergocryptine mesylate
2-Bromo-alpha-ergocryptine methanesulfonate
2-Bromo-alpha-ergocryptine methanesulfonate salt
2-Bromo-alpha-ergocryptine methanesulfonate salt, solid
2-Bromo-alpha-ergokryptine-mesilate
2-Bromo-alpha-ergokryptine-mesilate [German]
2-Bromoergocryptine
2-Bromoergocryptine Mesylate
2-Bromoergocryptine monomethanesulfonate (salt)
22260-51-1
25614-03-3 (Parent)
260B511
93201-EP2272825A2
93201-EP2305633A1
AC-29746
AC1L1KXP
AKOS015896276
alpha-Ergocryptine, 2-bromo-, methanesulfonate
AN-17214
AS-12186
B 2134
B6298
Bagren
BCP27904
BDBM70294
Bromergon
Bromocriptine (mesylate)
Bromocriptine mesilate
Bromocriptine mesilate (JP17)
Bromocriptine mesilate for system suitability, European Pharmacopoeia (EP) Reference Standard
Bromocriptine mesylate (USP)
Bromocriptine mesylate [USAN:USP]
Bromocriptine mesylate [USAN]
Bromocriptine mesylate salt
Bromocriptine mesylate, United States Pharmacopeia (USP) Reference Standard
Bromocriptine methanesulfonate
Bromocriptine(mesylate)
Bromocryptine mesylate
Bromocryptine methanesulfonate
C32H40BrN5O5.CH3SO3H
C32H40BrN5O5.CH4O3S
CAS-22260-51-1
CB 154
CB 154 methanesulfonate (salt)
CB-154
CB-154 mesylate
CCG-220121
CCG-221475
CCG-40056
CHEBI:3182
CHEMBL1200503
CHEMBL1347943
CHEMBL1587386
cid_5284352
cid_5284353
CS-6048
CTK8F8339
Cycloset
D00780
DSSTox_CID_197
DSSTox_GSID_20197
DSSTox_RID_75426
DTXSID6020197
EINECS 244-881-1
Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)-
EU-0100171
FFP983J3OD
HMS1568I04
HMS1920I05
HMS2091O07
HMS2095I04
HMS2234N03
HMS2235K15
HMS3260D03
HMS3266O07
HMS3712I04
HMS502C19
HY-12705A
I06-2158
KS-00001D04
LP00171
LS-7234
MFCD00069218
MLS-0003031.0001
MLS000069543
MLS000859961
MLS002153437
MLS002207063
MolPort-003-940-428
MolPort-006-123-738
MolPort-016-580-681
MolPort-038-935-649
NCGC00257268-01
NCGC00260856-01
NOJMTMIRQRDZMT-GSPXQYRGSA-N
NSC-169774
NSC-755915
NSC169774
NSC755915
oline-9-carboxamide methanesulfonate
Opera_ID_1111
Parlodel
Parlodel (TN)
Pharmakon1600-01500151
Pravidel
Prestwick_771
SCHEMBL40559
SMR000058761
SMR000326820
SPECTRUM1500151
SR-01000075356
SR-01000075356-1
SR-01000597796
SR-01000597796-1
SR-01000597796-2
SR-05000001578
SR-05000001578-1
Tox21_303597
Tox21_500171
UNII-FFP983J3OD

US Patents and Regulatory Information for bromocriptine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for bromocriptine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Us Pharms Holdings I PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Us Pharms Holdings I PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Federal Trade Commission
Express Scripts
QuintilesIMS
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.